Engineered Materials Offer New Framework for Controllable Cellular Immunotherapy

Cellular immunotherapies have transformed cancer care, yet their broader clinical reach remains constrained by centralized viral-vector manufacturing, suboptimal activity in solid tumors, and limited control over post-infusion cell behavior.

The authors organize their mechanism-centered review across distinct stages of the therapeutic pipeline, beginning with non-viral engineering platforms that modify immune cells ex vivo. Rather than relying on traditional viral vectors, the analysis highlights non-viral platforms including electroporation, physical device-based delivery, lipid nanoparticles, polymeric systems, transposon-based installation, and precision genome editing.

Transitioning from cell preparation to therapeutic deployment, the synthesis analyzes four distinct architectures enabled by in vivo nanocarriers. These modalities encompass transient programming of immune populations, sophisticated targeting logic to guide intervention, durable genetic programming in living systems, and post-infusion boosting to sustain functional performance.

For solid tumor indications, where adoptive therapies frequently encounter profound physical and immunological barriers, the authors examine cell–material hybrid strategies. Engineered biomaterial interfaces are evaluated for their capacity to enhance physical trafficking into tumor tissue, supply localized biochemical support, maintain cellular metabolic fitness amidst hostile microenvironments, and secure regional retention within target lesions.

The review also focuses on advanced materials-enabled control layers that govern immune cell actions after administration. These systems integrate remote physical actuation, molecular gating switches, layered safety mechanisms, and real-time monitoring capabilities.

Synthesizing these engineering domains, the authors conclude that the fundamental translational hurdle facing cellular immunotherapies is predictability rather than raw therapeutic potency alone. Translating these therapies into standard care requires reproducible manufacturing workflows, precisely controllable cell persistence, the practical feasibility of repeat dosing, and fully interpretable safety profiles. Engineered materials, the review argues, should be viewed not as secondary accessories, but as an enabling technological framework to transform cell therapy into a controllable, scalable class of biological medicines.

To support this transition, the authors specifically orient their mechanism-centered synthesis toward platform developers, translational researchers, and regulatory scientists. The stated objective is to clarify how engineered materials are reshaping cell therapy from a powerful biological intervention into a controllable therapeutic system.

Subject of Research: Materials-enabled cellular immunotherapy manufacturing and in vivo control

Article Title: Materials-enabled cellular immunotherapy: from manufacturing to in vivo control

Article References: Du, L., Wang, G., & Zhang, N. (2026). Materials-enabled cellular immunotherapy: from manufacturing to in vivo control. Discover Oncology. https://doi.org/10.1007/s12672-026-06154-y

Image Credits: AI Generated

DOI: 10.1007/s12672-026-06154-y

Keywords: cellular immunotherapy, biomaterials, in vivo control, non-viral delivery, cancer immunotherapy, lipid nanoparticles, adoptive cell therapy, solid tumors, genome editing, electroporation, polymeric systems, transposon systems, molecular gating, remote actuation, translational oncology, cell manufacturing